絞り込み

16644

広告

Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib - findings from an investigator initiated phase 2 study.

著者 Niemann CU , Herman SE , Maric I , Gomez-Rodriguez J , Biancotto A , Chang BY , Martyr S , Stetler-Stevenson M , Yuan CM , Calvo KR , Braylan RC , Valdez J , Lee YS , Jones J , Wong DH , Sun C , Marti GE , Farooqui MZ , Wiestner A
Clin Cancer Res.2015 Dec 9 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (18view , 0users)

Full Text Sources

Medical

Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental interactions for proliferation and survival that are at least partially mediated through B cell receptor (BCR) signaling. Ibrutinib, a Bruton's tyrosine kinase inhibitor, disrupts BCR signaling and leads to the egress of tumor cells from the microenvironment. While the on-target effects on CLL cells are well defined, the impact on the microenvironment is less well studied. We therefore sought to characterize the in vivo effects of ibrutinib on the tumor microenvironment.
PMID: 26660519 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード